Author:
Liu Yixuan,Xie Suhong,Li Lei,Si Yanhui,Zhang Weiwei,Liu Xin,Guo Lin,Liu Baochi,Lu Renquan
Abstract
Abstract
Background
This study investigates the effect of autologous bone marrow transfusion (BMT) on the reconstruction of both bone marrow and the immune system in patients with AIDS-related lymphoma (ARL).
Methods
A total of 32 patients with ARL participated in this study. Among them, 16 participants were treated with conventional surgery and chemotherapy (control group) and the remaining 16 patients were treated with chemotherapy followed by autologous bone marrow transfusion via a mesenteric vein (8 patients, ABM-MVI group) or a peripheral vein (8 patients, ABM-PI group). Subsequently, peripheral blood and lymphocyte data subsets were detected and documented in all patients.
Results
Before chemotherapy, no significant difference in indicators was observed between three groups of ARL patients. Unexpectedly, 2 weeks after the end of 6 courses of chemotherapy, the ABM-MVI group, and the ABM-PI group yielded an increased level of CD8+T lymphocytes, white blood cells (WBC), and platelet (PLT) in peripheral blood in comparison to the control group. Notably, the number of CD4+T lymphocytes in the ABM-PI group was significantly higher than that in the other two groups. Additionally, no significant difference in haemoglobin levels was observed before and after chemotherapy in both the ABM-MVI and ABM-PI groups, while haemoglobin levels in the control group decreased significantly following chemotherapy.
Conclusions
Autologous bone marrow transfusion after chemotherapy can promote the reconstruction of both bone marrow and the immune system. There was no significant difference in bone marrow recovery and reconstruction between the mesenteric vein transfusion group and the peripheral vein transfusion group.
Funder
National Natural Science Foundation of China
Science and Technology Commission of Shanghai Municipality
Publisher
Springer Science and Business Media LLC
Reference18 articles.
1. Berry SA, Fleishman JA, Moore RD, Gebo KA. Trends in reasons for hospitalization in a multisite United States cohort of persons living with HIV, 2001-2008. J Acquir Immune Defic Syndr. 2012;59(4):368–75.
2. Neuhaus J, Angus B, Kowalska JD, La Rosa A, Sampson J, Wentworth D, et al. Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. Aids. 2010;24(5):697–706.
3. Wang CC, Kaplan LD. Clinical management of HIV-associated hematologic malignancies. Expert Rev Hematol. 2016;9(4):361–76.
4. Joint United Nations Programme on HIV/AIDS (UNAIDS) and Joint United Nations Programme on HIV/AIDS (UNAIDS). Global AIDS Update 2016. Geneva; 2009.
5. WHO. Global health sector response to HIV, 2000–2015: focus on innovations in Africa. Geneva: World Health Organisation; 2015.